PF 6751979
Alternative Names: PF06751979Latest Information Update: 08 Mar 2018
At a glance
- Originator Pfizer
- Class Antidementias
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 30 Jan 2018 Discontinued - Phase-I for Alzheimer's disease (In the elderly, In volunteers, In adults) in Belgium and USA (PO) (Pfizer pipeline, March 2018)
- 16 Jul 2017 Adverse events, pharmacokinetics and pharmacodynamic data from a phase I trial in Alzheimer’s disease presented at the Alzheimer’s Association International Conference 2017 (AAIC 2017)
- 11 Jul 2017 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT03126721)